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Acquired immune deficiency syndrome (AIDS) remains an enormous health threat, despite the fact that available chemotherapeutic agents have increased in number and effectiveness in recent years. 1) Hepatitis B virus (HBV) infection is also a major health problem worldwide, particularly in Asia and Africa. In some regions of Asia and Africa, the prevalence of HBV infection reaches 9-12% of the population.
2) Among the antiviral agents, tenofovir disoproxil fumarate (TDF), an ester prodrug of tenofovir, was one of the few approved drugs clinically used against both human immunodeficiency virus (HIV) and HBV infections. Tenofovir {9-[(R)-2-(phosphonomethoxy)-propyl]adenine (TFV)} belongs to a class of nucleotide analogues in which a phosphonate group is bonded to the alkyl side chain of various purines and pyridimines.
3) TFV has certain advantages over many of the nucleoside analogues, including its longer intracellular half-life (Ͼ60 h) and serum half-life (17 h), allowing for less frequent once-daily dosing. 4) As TFV is not well absorbed in the intestine, TDF was synthesized to enhance the oral bioavailability of the drug.
Treatment against HIV or HBV infection is often a longterm effort. The need for the discovery and development of more efficacious, safer drugs cannot be overemphasized. TVP, a new ester prodrug of TFV, was synthesized and developed by Chinese scientists as a promising antiviral drug candidate. Pharmacokinetic assessment plays an important role in the evaluation and development of a prodrug. LC/MS/MS is considered the gold standard for the sensitive, selective determination of small molecular compounds in biological samples. Thus, in the present study, the aim was to develop and validate a specific, sensitive, rapid LC/MS/MS method for routine determination of TFV in plasma to support its development as an antiviral drug.
Several analytical methods for the quantification of TFV in plasma using LC/MS 5, 6) or LC/MS/MS [7] [8] [9] [10] [11] have been reported. However, in those reports, only the sensitivity 7) was higher, and the rest [8] [9] [10] [11] found lower sensitivity than achieved with our approach. Other reported methods involved the use of solid-phase extraction (SPE) cartridges to prepare samples for analysis to achieve the requisite sensitivity and selectivity, which is expensive and time-consuming. Moreover, Delahunty et al. used C-18 cartridges to prepare samples for TFV analysis, but encountered considerable variation in the results.
11) TFV is very polar, and therefore the major challenge is to circumvent ion suppression when quantitating the plasma concentration of TFV using LC/MS/MS methods. However, a discussion of ion suppression was absent in the reported LC/MS/MS bioanalytical assays for TFV. To avoid ion suppression, sufficient chromatographic separation is the most effective means. In this study, the utility of C 18 analytical columns with different packing types to obviate ion suppression was investigated. Another element in our approach is the reconstitution of the dried residue, which has a significant impact on LC peak shapes.
In this paper, we describe a specific, sensitive, rapid LC/MS/MS method for the determination of TFV in monkey plasma. This method utilized readily available adefovir as an IS, which has a chemical structure similar to that of TFV. The plasma sample preparation procedure was simple and rapid, requiring only the precipitation of proteins with methanol which is suitable for the analysis of large batches of samples. The method was successfully applied to the analysis of more than 1000 samples generated during preclinical trials.
MATERIALS AND METHODS
Chemicals TFV, TDF, TVP, and internal standard (IS) were synthesized and supplied by the Beijing Institute of Pharmacology and Toxicology (Beijing, P. R. China). Their purities were determined using HPLC-UV and were at least 98%. Methanol and acetonitrile (HPLC grade) were purchased from Fisher Scientific (Fairlawn, NJ, U.S.A.). All other chemicals and solvents used were of analytical grade and were purchased from Beijing Chemical Reagent Co. (Beijing, P. R. China). Milli-Q (Millipore, Bedford, MA, U.S.A.) deionized water was used throughout the study.
Instrumentation An Agilent 1100 system (Palo Alto, CA, U.S.A.) consisting of a vacuum degasser, a quaternary pump, and an autosampler was used for solvent and sample delivery. An AB MDS Sciex API 3000 triple-quadrupole mass spectrometer (Concord, Ontario, Canada) equipped with a Turbo IonSpray source was used for mass analysis and detection. Analyst 1.4 software (AB MDS Sciex) was used for data acquisition.
Liquid Chromatographic Conditions Chromatographic separation was achieved on a Discovery C 18 column (250ϫ4.6 mm, 5 mm; Supelco, Bellefonte, PA, U.S.A.) and a C 18 guard column (4ϫ3.0 mm, 5 mm; Phenomenex, Torrance, CA, U.S.A.). The column temperature was maintained at 25°C. The mobile phase was an isocratic solvent system consisting of methanol-water-formic acid (20 : 80 : 0.5, v/v/v), at a flow rate of 0.5 ml/min.
Mass Spectrometric Conditions
The mass spectrometer was operated in the positive ion mode. The tuning parameters were carefully optimized for TFV. Ultrapure nitrogen was used as a nebulizer, curtain, and collision-activated dissociation (CAD) gas at 8, 11, and 5 instrument units, respectively. The optimized Turbo IonSpray voltage and temperature were set to 4500 V and 350°C, respectively. Quantitation was performed with multiple reaction monitoring (MRM) of the transitions of m/z 288→176 and 274→162 for TFV and the IS, respectively. Each transition was monitored with a 150-ms dwell time.
Preparation of Standard and Quality Control Samples Stock solutions of TFV and the IS were prepared at 1 mg/ml in methanol-water (1 : 1, v/v) and stored at Ϫ20°C. A series of standard working solutions for TFV was prepared by diluting stock solutions with water to concentrations in the range of 0.02-500 mg/ml. The IS solution was brought to a final concentration of 2 mg/ml in water. Structural formulae of TFV and IS are shown in Fig. 1 . All working solutions were stored at 4°C and brought to room temperature before use.
Calibration standards and quality control (QC) samples were prepared by spiking 50 ml of the working solutions and 50 ml of the IS into 200 ml of drug-free monkey plasma. Matrix-matched TFV calibration standards were prepared in plasma at concentrations of 0.005, 0.0125, 0.025, 0.05, 0.125, 0.25, 0.5, and 1.25 mg/ml. QC samples were prepared in plasma at concentrations of 0.0125, 0.125, and 1.25 mg/ml. Sample Preparation IS solution 50 ml was added to a 200 ml aliquot of plasma. The sample mixture was deproteinized with 0.5 ml of methanol, and the precipitate was removed by centrifugation at 6000 g for 10 min. The supernatant was transferred to another tube and evaporated under a gentle stream of air at 45°C until dry. The residue was dissolved in 150 ml of water and vortex mixed. A 20 ml aliquot of the solution was injected into the LC/MS/MS system for analysis.
Method Validation During the prestudy validation, the calibration curves were defined in three runs on the basis of triplicate assays of the spiked plasma samples, and on the same day, QC samples from 3 concentrations (Table 1) were determined in replicates (nϭ6) to calculate the method accuracy and precision. Calibration curves were constructed using a 1/x 2 weighted linear regression of the peak-area ratios of the analyte to the IS versus the plasma concentration of the analyte. During routine analysis, each analytical run included a set of calibration samples, a set of QC samples in duplicate, and the unknown samples. Extraction recovery was measured by comparing the response of the analytes spiked before and after sample preparation. Matrix effects were assessed using a method similar to that reported by Matuszewski et al. The maximum plasma concentration (C max ) and the corresponding time (T max ) were obtained from observed data. The area under the curve from time zero to the last sampling time (AUC 0-t ) was determined using the linear trapezoidal rule. The terminal elimination rate constant (K e ) was estimated with least-squares regression of values in the terminal log-linear region of plasma concentration-time curves. The terminal elimination half-life (t 1/2 ) was calculated to be 0.693/K e .
RESULTS AND DISCUSSION

Bioanalytical Method Development Electrospray ionization (ESI)-MS/MS was used to analyze the compounds.
To determine the analyte using the MRM mode, the full scan and product ion spectra of the analyte and the IS were investigated. Since TFV has both amino and phosphonic acid groups in its structure, the possibility of using positive or negative ion detection was first evaluated. It was found that the positive ESI offered higher sensitivity than the negative mode. In positive ESI, TFV and the IS formed predominant protonated molecules [MϩH] ϩ at m/z 288 and 274, respectively, in the full scan spectra. The [MϩH] ϩ ions were therefore chosen as the precursor ions to obtain their major fragment ions for MRM analysis. The product ion scan spectra of [MϩH] ϩ for TFV showed several major fragment ions at m/z 136, 176, 206, and 270 (Fig. 1) . A fragmentation study of TFV was reported. 7) The fragment ion at m/z 176, formed by breaking the single carbon-oxygen bond in the side chain, was present in the greatest abundance. The fragment ion at m/z 136 showed a relative intensity of about 50% of the base peak and the other fragments showed less than 20%. The most abundant fragment ion at m/z 162 was selected for MRM analysis for the IS. Figure 1 displays product ion spectra of [MϩH] ϩ ions from TFV and IS. TFV is very polar, and therefore the major challenge is to circumvent ion suppression when quantitating the plasma concentration of TFV using LC/MS/MS methods. Matuszewski et al. proposed that the matrix effect may be eliminated or minimized by improving the sample extraction procedure, employing stable isotope-labeled internal standards, performing the assay under more efficient chromatographic conditions, or changing the LC/MS interface.
12) The largely polar character of TFV makes it difficult to extract from plasma with organic solvents. SPE is necessary and important because this technique not only purifies but also concentrates the sample. 7, 10) However, sample preparation and the extraction procedure are time-consuming. Moreover, Delahunty et al. attempted to use C-18 cartridges to prepare samples for TFV analysis, but encountered considerable variation in the results. 11) In the present work, protein precipitation was used for the extraction of TFV from plasma, which offered satisfactory extraction recoveries for the analytes. Moreover, when methanol was chosen for protein precitation, the extraction recovery rates were higher than when acetonitrile was used. This was not previously reported in the literature. Stable isotope-labeled IS, as utilized by Delahunty et al., could compensate for inter-sample variability resulting from ion suppression, but would not change the sensitivity. 8) In addition, there are concerns such as the purity and price connected with the use of labeled IS in bioanalysis. To avoid ion suppression, sufficient chromatographic separation is the most effective means for the present purposes.
A short HPLC column can reduce analytical cycle time; however, it may lead to significant ion suppression. Therefore chromatographic separation was attempted on the following four C 18 columns with 250ϫ4.6 mm column dimensions (viz., Discovery, Diamonsil, Zorbax, and Nucleodur) to achieve the best efficiency and peak shape. The four columns showed distinct retention patterns due to their different packing types (Fig. 2 ). Significant ion suppression was observed on the latter three C 18 columns when using methanol-waterformic acid (20 : 80 : 0.5, v/v/v) as the mobile phase. The Discovery C 18 column proved to be the most suitable stationary phase for retaining the analytes.
Different mobile phases were evaluated to improve HPLC separation and enhance MS sensitivity. It was also reported that a volatile buffer like acetic acid/hydroxylamine or ammonium formate could enhance the sensitivity of ESI-MS analysis of antiretroviral drugs. 5, 13) Thus separation was attempted using various combinations of methanol-acetonitrile, acidic buffers, and additives. Methanol was selected as the organic modifier because its ability to ionize the analytes was superior to that of acetonitrile. Additionally, formic acid was found to be necessary to prevent peak tailing and enhanced the positive ionization of TFV. Finally methanolwater-formic acid (20 : 80 : 0.5, v/v/v) was chosen as the mobile phase, due to the better separation, higher sensitivity, and more stable mass spectral response. Under the current chromatographic conditions, the retention times of TFV and the IS were approximately 6.6 and 6.2 min, respectively. The selectivity of the method for endogenous plasma compounds was found to be satisfactory.
For redissolution of the dried residue, we tested different solvents with water and various percentages of methanol in water as components. Redissolution of TFV was best achieved in water, which offered superior peak shape for TFV and the IS (Fig. 3) .
To achieve acceptable performance, especially in LC/MS/ MS, an IS that mimics the analyte during sample extraction, chromatographic elution, and mass spectrometric detection should be selected. An appropriate IS will compensate for potential inconsistent responses due to matrix effects and will not cause interference with the analyte and vice versa. Although a stable isotope-labeled compound would be an ideal IS for quantitation in complex matrices in LC/MS/MS analysis, it is not readily available in most laboratories.
Therefore structural analogues were screened to find suitable compounds for use as IS. Adefovir, a demethylated analogue of TFV, was finally selected as the IS. Also, both drugs are used concurrently in HIV/HBV-coinfected patients with no indications of drug-drug interactions. 14) Moreover, adefovir was used as an IS for TFV assays by Yadav et al. 7) and Delahunty et al.
11)
Assay Specificity and Matrix Effect Method specificity was determined by comparing the MRM chromatograms of blank samples with those of spiked samples. No interference was detected from endogenous substances within the analytes and IS (Fig. 4) .
Matuszewski and coworkers outlined the importance of including the evaluation of matrix effect in any LC/MS/MS method in an excellent paper.
12) The matrix effect was assessed as follows: to the blank matrix from five different in- dividuals, analytes were added at three concentrations (0.0125, 0.125, 1.25 mg/ml), making a total of 15 samples. These samples were subjected to the analytical procedure and compared with the standard working solutions. The results indicated that coeluting endogenous species did not interfere with the ionization of the analytes and IS. The chosen chromatographic conditions provided adequate separation between the solvent front and the analytes. This could also have reduced the risk of ion suppression.
Linearity of Calibration Curves and the Lower Limit of Quantification
The linear range was 0.005-1.25 mg/ml for TFV in the monkey plasma with correlation coefficients of Ͼ0.99. The lower limit of quantification, defined as the lowest concentration analyzed with Ϯ15% accuracy and Յ15% precision, was 0.005 mg/ml for TFV.
Precision and Accuracy Assay precision and accuracy were determined by using QC samples at three concentrations in replicate (nϭ6) by performing complete analytical runs on the same day and on three consecutive days. The data from these QC samples were analyzed using one-way analysis of variance (ANOVA). The intra-and inter-day precisions were less than 11.35% for each QC level. The accuracy, as assessed by calculating the percentage deviation observed in the analysis of QC samples, was within Ϯ2.84% for each QC level. The results are summarized in Table 1 .
Recovery and Stability A simple one-step protein precipitation procedure was applied to extract analytes from plasma. Mean extraction recovery rates of TFV were 84.58Ϯ1.59%, 87.80Ϯ5.42%, and 86.58Ϯ9.23% at the concentrations of 0.0125, 0.125, and 1.25 mg/ml, respectively. The extraction recovery rate of the IS was 95.91Ϯ7.38%. The results of stability experiments showed that no significant degradation occurred during the extraction and sample storage processes for TFV in plasma samples. Stability data 
